Check out Medtech Insight's US FDA Warning Letter Data Tracker here.
Warning Letter Roundup & Recap – January 2023
The US Food and Drug Administration published three device-related warning letters in January – two that went to divisions of endoscope vendor Olympus, and one to a Maryland vision treatment firm.
More from Regulation
• By
Its move comes as the Swiss recognize the need to ensure adequate supplies on medical devices in its country.
• By
As the EU Life Sciences Strategy aims to drive innovation, the medtech sector is pushing for a pivotal role in a mission intended to embrace green and digital transitions, address regulatory obstacles and reduce dependency on external sources.
• By
The FDA's final LDT ruling was struck down in federal court last month. For now, diagnostic companies can commercialize under CLIA regulations or apply for FDA approval. McDermott and Tribun Health have shared insights on the risks, pros and cons of both regulatory routes.
• By
Ireland’s NSAI reinstated under IVD Regulation designation list